the masses at bay through endless mindless bliss. Sex was recreational, love was obsolete, and the notion of a family obscene. Unexpectedly, however, in an all too brief an opening chapter, we are being treated to a profound display of clairvoyance in which Huxley literally lays out the future of reproductive medicine. The setting by any other name is a familiar one. The so-called Central London Hatchery, replete with its ''Fertilizing Room,'' incubators, work tables, slides, test tubes, bottles, and microscopes, could readily pass for today's embryology laboratory. Eggs are secured via ex vivo cultures of whole ovaries. Embryos in turn are secured via, imagine, in vitro fertilization only to be followed by in vitro gestation that is ectogenesis. Even genome editing and human cloning receive some mention. Clearly, the arc of Huxley's vision went well beyond the present state of the art. Hard as we might try, we are still catching up to him.
The realization of in vitro fertilization (IVF) by Edwards and Steptoe constituted a remarkable indeed disruptive innovation. 3 Life thereafter was never the same again. Many of us were fortunate enough to witness this breakthrough in our lifetime. Huxley, regrettably, passed on 15 years earlier. Recognized by a Nobel Prize in physiology and medicine (Figure 4 ), IVF all but vanquished the scourge of infertility. 4 No less important, IVF gave rise to multiple often improbable therapeutic and diagnostic breakthroughs, many of which could not have been foreseen by its originators let alone Huxley.
Astoundingly, IVF, remarkable a feat as it was, could well be supplanted before too long by a literal watershed of unprecedented breakthroughs which are materializing at a far more ferocious clip than ever before. With your indulgence, let me expand some on this latter point. Examined in hindsight, the cumulative scientific and medical insights of our time have effectively been assembled over the last 70 years, that is, since the conclusion of the Second World War. It seems unlikely that the doubling of this knowledge complement will require yet another 70 years in that the pace of discovery is accelerating. In this context, Moore's law comes to mind according to which computing power, as measured by chip density, has been doubling every 2 years. 5 The limitations of this metaphor notwithstanding, it is probable that viewing tomorrow through yesterday's prism may lead one to conclude that the future is further away than it truly is. In a word, the next disruption of reproductive medicine is likely just around the corner and as such may come into being sooner rather later.
In keeping with the aforementioned thesis, it may be time for us to explore the extant leading edge of reproductive medicine. In particular, we may wish to focus on the emergence of mitochondrial replacement therapy, of genome editing, and of in vitro gametogenesis, all of which are unfolding at breakneck speed in front of our very eyes. In particular, let us explore how these emerging technologies stand to alter reproductive medicine as we know it, the nature of the regulatory constructs at work and the ethics of it all.
Mutant mitochondrial DNA gives rise to a broad range of inborn errors of energy metabolism, the manifestations of which are highly disabling and often fatal. 6 Cure of those affected remains elusive. 6 Moreover, the utility of preimplantation genetic diagnosis remains the subject of an active debate. 7 However, recently developed mitochondrial replacement therapy, MRT for short, has raised the prospect of disease-free progeny for women carriers by replacing mutant oocytic or zygotic mitochondrial DNA with a donated wild-type counterpart. [8] [9] [10] Investigators from Oregon Health and Science University, Newcastle University, and Columbia University carried out the seminal preclinical experiments to which members of this very society have made significant contributions. [8] [9] [10] The regulatory adjudication of MRT in the United Kingdom, several years in the making, was nothing short of exemplary in its focus on safety, ethics, and public receptivity. 11 On February 3 of this year, the House of Commons voted to approve the conduct of MRT under the auspices of the Human Fertilisation and Embryology Authority. 12 The next day, coverage by both lay and scientific media proved extensive. The House of Lords followed suit shortly thereafter to similar fanfare. 13 Early clinical trials could commence as early as November 1 of this year. The first postprocedural birth could potentially come to pass as early as 2016. 14 The vetting process of MRT in the United States, underway for all of 1 year, remains work in progress. Pursuant to a meeting of the relevant advisory committee now over a year ago, the Food and Drug Administration (FDA) commissioned the Institute of Medicine to assess the ethical and social policy implications of MRT. 15 No further FDA action is expected until this task has been concluded. In the interim, any and all submitted investigational new drug applications (INDs) remain on hold.
These developments are nothing short of historic and their significance multifaceted. First, MRT represents the first ever crossing of the ''germline barrier.'' Second, MRT constitutes the first ever form of organelle, indeed whole cytoplasmic replacement therapy. Third, MRT represents the first ever gene therapy that is IVF based. Fourth, MRT serves as a regulatory test case for all future cutting-edge reproductive technologies. Fifth, MRT irrevocably alters the face of assisted reproduction from a discipline focused on infertility to one with a far broader portfolio. Not even Huxley saw it coming.
The ethics of MRT has been the subject of intense debate. 16 It is after all about germ line therapy, the outcome of which will be transmitted in perpetuity. Arguments in favor of MRT rest with the ethical doctrines of procreative autonomy, altruism, and beneficence. Objections to MRT, especially on safety grounds, have not held up. Safety, the guarantor of nonmaleficence, could not have been more thoroughly vetted short of the First-in-Human imponderable. 17 Moreover, Parfitian ''nonidentity'' principles suggest that MRT need not be viewed as harmful unless it were to doom a newborn to a life that is not worth living. 16 Concerns over the nature of the parental construct, often conveyed by the term ''three parent babies,'' have also been placed in biological and legal perspective. After all, mitochondria harbor but minute amounts of maternally derived DNA none of which is any more relevant to the individual humanity of the newborn than resident retroviral nuclear DNA. In a word, biology cannot be invoked to characterize the mitochondrial donor as a mother. Indeed, no such legal status has been accorded by Parliament to prospective mitochondrial donors. 12 Finally, unease over runaway boundary breach has been addressed by pointing out that the approval of MRT does not in any fashion pave the way for the approval of genome editing any more than the approval IVF mandated the approval of MRT. 11 The contemporary era of genome editing to which we now turn was effectively unleashed a mere 3 years ago. The breakthrough Science paper which made it all possible, seniorauthored by Jennifer Doudna and Emmanuelle Charpentier, describes a family of bacterial endonucleases capable of generating RNA-guided/sequence-specific DNA breaks. 18 Suddenly, the tantalizing possibility of effecting allele-specific deletions or insertions, at will, is no longer science fiction. Nor is this capacity limited to a select few by virtue of its relative simplicity. In a word, the era of replacing mutant DNA sequences with wild-type counterparts or vice versa appears to be upon us. New possibilities include multiplex knockouts or knockins 19 as well as genome-scale transcriptional gene repression and activation. 20 Even chromosomal rearrangements 21 and genome-wide screens of tumor growth and metastasis are now feasible. 22 The implications are obvious but hardly straightforward. It is no longer just about the possible. Instead, it is about what is ethically defensible and publicly acceptable. But more on that later.
Unlikely to stand idly by, reproductive medicine joined the fray. In one relevant example now all of 1 year ago, the clustered regularly interspaced short palindromic repeats/CRISPRassociated protein 9 (CRISPR/Cas9) platform has been successfully deployed to disrupt 2 target genes in Cynomolgus Monkey zygotes. 23 Two null mutant offspring ensued. 23 The ethics of genome editing in the human embryo is complex and divisive. After all, the substrate of genome editing is nuclear DNA, that is, the blueprint of who we are in every sense of the word. Moreover, germ line transmission is a given. Some have already called for a moratorium on genome editing of the human embryo. 24 Yet other leading scientists, including 2 Nobel Prize laureates, have advocated a self-imposed ban followed by a vigorous national debate. 25 One forward-looking ethical strategy might seek to limit potential interventions to maladies for which neither prevention nor treatment let alone cure is available. 26 Buttressed by an uncompromising focus on nonmaleficence through safety assurance, such altruistic indeed beneficent approach, could be viewed as an extension of the principles established by MRT. 10, 11 In contrast, interventions with trait selection and/or enhancement in mind may well be precluded. Whether or not the principle of procreative beneficence-advocated by some-can be viewed as divorced of eugenic intent remains to be debated. 27 With MRT and genome editing coming to the fore, it is little wonder that in vitro gametogenesis, or IVG for short, has not dominated the headlines. While the phraseology of ''threeparent babies'' and of ''designer babies'' appears nothing short of ubiquitous, the prospect of ''eggs and sperm from a buccal smear'' has hardly made a dent. It should have. An unprecedented early translational installment of stem cell science, this potentially momentous development promises nothing less than to transform the fields of reproductive and regenerative medicine. It deserves our undivided attention. Even Huxley never wandered this far.
As this audience knows all too well, the successful in vivo differentiation of the germ cell lineage requires timely signaling along a proscribed, multistepped fate-specification pathway. The proximate extragonadal segment of this developmental course-the induction of primordial germ cells-has now been successfully recapitulated in vitro in both the mouse and the human models using cultured embryonic or induced pluripotent stem cells. [28] [29] [30] Gametogenic competence was validated by further cultivation in vivo and the generation of live pups in the mouse paradigm. 28, 29 These feats were directly attributable to prior knowledge of the molecular cues at work in vivo and the application thereof in vitro. 31 Far less is known however about the signals guiding the terminal intragonadal conversion of primordial germ cells into competent gametes. 32 Not surprisingly, that developmental sequence has yet to be recapitulated in vitro. Realizing the full promise of IVG will require that the critically timed signals exchanged between the somatic gonadal cells and their germ cell counterparts be thoroughly elucidated.
Viewed in the light of its potential implications, IVG stands to advance the science of embryonic germ cell elements currently constrained by their limited availability. Indeed, IVG raises the prospect of an all but inexhaustible supply of germ cell constituents for a detailed investigation of their cognate biology.
Concurrently, IVG promises to transform the field of reproductive medicine, if nothing else, by substituting for lost or impaired germ cell function. The special case of cancer survivors appears particularly pressing. IVG might also lead to the deconstruction of the current IVF paradigm by eliminating the need in stimulating the ovary and retrieving the eggs thereof. The use of similarly derived donor eggs may also be rendered obsolete. According to this view, IVF may reemerge as a laboratory-based procedure.
The challenges facing IVG are multiple. First, terminal gametogenesis-the in vitro conversion of primordial germ cells into fully functional gametes-would have to be accomplished. Second, meiosis, the hallmark of gametogenesis, would have to be meticulously replicated and carefully validated. 33, 34 Third, the generation of stem cell-derived somatic gonadal cells may have to be considered with cocultures in mind. 35 Fourth, greater attention may have to be paid to simulating the gonadal ''niche'' microenvironment the role of which in optimizing oocyte differentiation is widely appreciated. 36 The ethical overlay of IVG sets off both familiar and novel alarm bells. 37, 38 Nonmaleficence in the name of safety is bound to lead the way in the service of altruistic and beneficent indications and in the name of procreative autonomy. On the other hand, the selection of gametes or embryos with the view of securing desirable traits will require a vigorous public debate. In this regard, the possibility of generating and likely destroying large numbers of embryos from stem cellderived gametes appears especially challenging. The very scale of this phenomenon suggests that rigorous oversight may well be required.
Faced with the prospect of novel reproductive technologies, societal values and mores often find themselves lagging behind the science. Bridging this gap is never easy especially in the face of polarization across the prochoice/prolife divide. Still, matters of conscience must and will feature prominently in any and all debates relevant to novel reproductive technologies. Given to a principled view of the sanctity of human life, advocates invariably oppose human embryo research and human embryo destruction, a position they have every right to hold. It follows that articles of conscience must be respected for what they are and for the important role they will inevitably play in the conversation.
Throughout history, progress in all matters, reproduction has met not only with convictions of conscience but also with a deep-seated fear of the unnatural, a point most eloquently made by the English science writer Philip Ball. 39 Call it fear for the traditional family, fear of revising the laws of nature, or fear of altering the natural order known to man for millennia. Call it fear of the unknown. Fear of tampering with creation. Fear of trust betrayed and of technology running unchecked. A fear resistant to cerebral and utilitarian arguments and one which is often aggravated by charged phrases such as ''three-parent babies,'' ''designer babies,'' ''slippery slope,'' ''playing god,'' or ''crossing a line.'' If there is a silver lining here, it is that heterodoxy is not forever and that utilitarianism sometimes wins the day. Precedents include but are not limited to contraception and to IVF, both of which have been vigorously opposed at the time of their inception.
By many accounts, it is high time to strike and maintain a vigorous national conversation on the ethical challenges and social policy implications of emerging reproductive technologies. Some have suggested that the process includes deliberation by august organizations such as the Institute of Medicine, the Presidential Commission for the Study of Bioethical Issues, or the Hastings Center to name a few. However, we must go well beyond this narrow circle to the public at large in ways we have never done before. Technology after all is no longer a barrier. Nothing less will do as millennia of familiarity with conventional reproduction are being disrupted. In the final analysis, it is the outcome these national conversations which will determine whether or not novel reproductive technologies will win over sufficient hearts and minds to carry the day.
By the time the centennial of Brave New World rolls around, 16 years hence, Huxley's vision of the future of reproductive medicine will have come full circle. Incompletely realized in some cases and exceeded in others, it is no matter. Huxley's foresight remains unmatched. If only he could rejoin us in the here and now to expound on these matters in his inimitable fashion. If there ever was an argument for immortality, this is it. He has seen the future and it is now.
Thank you all very much for you attention.
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